Back

Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Pharmacology and pharmacotherapy Antidiabetic Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Mauro Feola

Cardiology Department, Mondovi (Italy)

5 More presentations in this session

Presentation thumbnail
Real-life adverse events with SGLT-2 inhibitors: different safety profiles according to their indications?
Mr O. Chebbo (Montpellier, FR)
Abstract Slides Video
Presentation thumbnail
Assessing doctors' knowledge and confidence regarding SGLT2 inhibitor prescribing practices, side-effects, and ESC guidelines
Doctor E. Higgisson (Dublin, IE)
Abstract Slides Video
Presentation thumbnail
Efficacy of ARNI in patients using LVAD: a systematic review and meta-analysis
Doctor E. Hasabo (Galway, IE)
Abstract Slides Video
Presentation thumbnail
Intravenous iron therapy for patients with heart failure and iron deficiency: an updated meta-analysis of randomized controlled trials
Mr G. Yeap (GB)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of SGLT2-i in patients using LVAD: a systematic review and meta-analysis
Doctor E. Hasabo (Galway, IE)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacology and pharmacotherapy

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Case 1 - a middle-aged male with T2DM: polypharmacy in a primary prevention setting
thumbnail
Congress Presentation
Hypertension and glucose
thumbnail
Congress Presentation
Cardiovascular risk reduction: should we target pre-diabetes?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources